1. Home
  2. NTNX vs JAZZ Comparison

NTNX vs JAZZ Comparison

Compare NTNX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutanix Inc.

NTNX

Nutanix Inc.

HOLD

Current Price

$39.29

Market Cap

10.1B

Sector

Technology

ML Signal

HOLD

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

HOLD

Current Price

$178.72

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTNX
JAZZ
Founded
2009
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
10.4B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
NTNX
JAZZ
Price
$39.29
$178.72
Analyst Decision
Buy
Strong Buy
Analyst Count
16
13
Target Price
$64.33
$215.92
AVG Volume (30 Days)
4.2M
974.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
227.45
N/A
EPS
0.57
N/A
Revenue
$2,537,927,000.00
$1,618,693,000.00
Revenue This Year
$13.91
$6.17
Revenue Next Year
$13.28
$7.66
P/E Ratio
$68.49
N/A
Revenue Growth
18.11
N/A
52 Week Low
$35.39
$95.49
52 Week High
$83.36
$198.00

Technical Indicators

Market Signals
Indicator
NTNX
JAZZ
Relative Strength Index (RSI) 44.11 50.46
Support Level $35.84 $176.67
Resistance Level $42.63 $182.99
Average True Range (ATR) 1.76 6.39
MACD 0.19 -0.90
Stochastic Oscillator 48.20 28.45

Price Performance

Historical Comparison
NTNX
JAZZ

About NTNX Nutanix Inc.

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: